Abstract
A potent antitumor CD4+ T-helper cell immune response is created by inducing tumor cells in vivo to a MHC class II+/Ii− phenotype. MHC class II and Ii molecules were induced in tumor cells in situ following tumor injection of a plasmid containing the gene for the MHC class II transactivator (CIITA). Ii protein was suppressed by the antisense effect of an Ii-reverse gene construct (Ii-RGC) in the same or another co-injected plasmid. The MHC class II+/Ii− phenotype of the tumor cells was confirmed by FACS analysis of cells transfected in vitro and by immunostaining of tumor nodules transfected by injections in vivo. Subcutaneous Renca tumors in BALB/c mice were treated by intratumoral injection with CIITA and Ii-RGC, in combination with a subtherapeutic dose of IL-2, to up-regulate the activation of T cells. Significant tumor shrinkage and decrease in rates of progression of established Renca tumors were seen in the groups injected with Ii-RGC, compared with groups in which only IL-2 plus empty plasmid controls were injected. Our method provides an effective immunotherapy warranting further development for human cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CIITA:
-
MHC class II transactivator
- DMRIE:
-
1,2-dimeristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide/cholesterol
- FCS:
-
fetal calf serum
- RGC:
-
reverse gene construct
References
Armitage P, Berry G (1994) Statistical methods in medical research, 3rd edn. Blackwell, Malden, MA, pp 348–350
Armstrong T D, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S (1997) Major histocompatibility complex Class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94:6886–6891
Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998) MHC Class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 160: 661–666
Baskar S, Azarenko V, Garcia Marshall E, Hughes E, Ostrand-Rosenberg S (1994) MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 155:123–133
Bertolino P, Rabourdin-Combe C (1996) The MHC Class II-associated invariant chain: a molecule with multiple roles in MHC Class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 16:359–379
Chang CH, Flavell RA (1995) Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181:765–767
Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S (1992) Invariant chain alters the malignant phenotype of MHC Class II+ tumor cells. J Immunol 149:2391–2396
Dezso B, Haas GP, Hamzavi F, Kim S, Montecillo EJ, Benson PD, Pontes JE, Maughan RL, Hillman GG (1996) The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases. Clin Cancer Res 2:1543–1552
Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158
Gilboa E (1999) How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48:382–385
Hillman GG., Kallinteris NL., Li J., Wang Y., Lu X., Wu S., Wright JL., Slos P., Gulfo JV., Humphreys RE., and Xu M. (2003) Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther (in press)
Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE (1999) IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 163:6378–6385
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 188:2357–2368
Jiang Z, Xu M, Savas L, LeClair P, Banner BF (1999) Invariant chain expression in colon neoplasms. Virchows Arch 435:32–36
Ju DW, Wang BM, Cao X (1998) Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J Cancer Res Clin Oncol 124:683–689
Koch N, Lauer W, Habicht J, Dobberstein B (1987) Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii): an alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. EMBO J 6:1677–1683
Koch N, Koch S, Hammerling GJ (1982) Ia invariant chain detected on lymphocyte surfaces by monoclonal antibody. Nature 299:644–645
Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ (1996) Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 15:6144–6154
Long EO, Rosen-Bronson S, Karp DR, Malnati M, Sekaly RP, Jaraquemada D (1991) Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum Immunol 31:229–235
Martin BK, Frelinger JG, Ting JP (1999) Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol 162:6663–6670
Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, Ting JP (1997) Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 6:591–600
Overwijk WW, Theoret MR, Restifo NP (2000) The future of interleukin-2:enhancing therapeutic anticancer vaccines. Cancer J Sci Am [Suppl 1]: S76–80
Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi, L, Pipeling MR, Hanyok LA, (1999) Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 170:101–114
Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588–594
Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex Class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486–1493
Qi L, Ostrand-Rosenberg S (2000) MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic 1:152–160
Qi L, Rojas JM, Ostrand-Rosenberg S (2000) Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 165:5451–5461
Qiu G, Goodchild, J, Humphreys RE, Xu M (1999) Cancer immunotherapy by antisense suppression of Ii protein in MHC-Class-II-positive tumor cells. Cancer Immunol Immunother 48:499–506
Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE (1998) Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Cancer Gene Ther 5:321–330
Spiro RC, Sairenji T, Townsend P, Reisert PS, Humphreys RE (1984) The Ii nature of p35 on hairy leukemic cells. Semin Oncol 11:427–432
Wang RF (2001) The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 22:269–276
Xu M, Qiu G, Jiang Z, Von Hofe E, Humphreys RE (2000) Genetic modulation of tumor antigen presentation. Trends Biotechnol 18:176–172
Zhou H, Glimcher LH (1995) Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 25:45–53
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was funded in part by NCI grants R43 CA85100 and R43CA 89856.
Rights and permissions
About this article
Cite this article
Lu, X., Kallinteris, N.L., Li, J. et al. Tumor immunotherapy by converting tumor cells to MHC class II–positive, Ii protein–negative phenotype. Cancer Immunol Immunother 52, 592–598 (2003). https://doi.org/10.1007/s00262-003-0404-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-003-0404-9